Adicet Bio Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Adicet Bio Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.465 $ to 9.70 $ · Last price: 6.40 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Adicet Bio Inc ACET | 0.1 | – | -1.2 | – | 0.0 | – | -52.8 |
| Vertex Pharmaceuticals Inc VRTX | 133.5 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 36.8 |
| Moderna Inc MRNA | 78.3 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| Regeneron Pharmaceuticals Inc REGN | 78.2 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.5 | 37.2 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 41.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.5 | 65.5 | 32.4 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.9 | 64.3 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 41.9 | 34.6 | 19.2 | 57.0 | 20.7 | 7.3 | 36.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 547 | 0 | 0 | 0.00 | 8 | 304 | 541 |
| 2017 | 559 | -19 | -34 | -20.04 | -12 | 50 | 55 |
| 2018 | 8 | -15 | -9 | -4.99 | -18 | 104 | 110 |
| 2019 | 1 | -31 | -28 | -24.26 | -28 | -60 | 82 |
| 2020 | 18 | -39 | -37 | -80.17 | -42 | 110 | 154 |
| 2021 | 10 | -61 | -62 | -32.05 | -51 | 303 | 339 |
| 2022 | 25 | -73 | -70 | -27.18 | -45 | 292 | 331 |
| 2023 | 0 | -152 | -143 | -53.03 | -94 | 170 | 207 |
| 2024 | 0 | -128 | -117 | -21.33 | -92 | 187 | 220 |
| 2025 | 0 | -122 | -117 | -16.95 | -95 | 159 | 192 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -5.44 | 70.70 | 0 | – | – | -22 | -22 |
| 2024: Q4 | -0.32 | 53.60 | 7 | -49.50 | -441.50 | -24 | -24 |
| 2025: Q1 | -4.96 | 11.40 | 0 | – | – | -25 | -27 |
| 2025: Q2 | -0.34 | 93.60 | 0 | – | – | -27 | -27 |
| 2025: Q3 | -0.29 | 94.70 | 0 | – | – | -22 | -23 |
| 2025: Q4 | -2.94 | -818.80 | 0 | -100.00 | – | -21 | -21 |
| 2026: Q1 | -1.88 | 62.10 | 0 | – | – | -22 | -22 |
| 2026: Q2 | -1.99 | -485.30 | 0 | – | – | -41 | -42 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -6.36 | -8.05 – -5.11 | 0 | 62.5% | 6 |
| 12/31/2027 | -4.04 | -7.67 – 1.07 | 29 | 36.5% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0%
- More than 10% revenue growth is expected for the coming year no data
- Share count grows by less than 3% a year 39.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 144 m net cash
- Operating cash flow covers the profits of the last three years 95 m
- Return on capital at 15% or higher, or up versus two years ago -71.5%
- Insiders hold at least 10% or are net buyers 1.1%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -73.4%
- ROCE > 15% -71.5%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Adicet Bio, Inc., ein biotechnologisches Unternehmen im klinischen Entwicklungsstadium, entdeckt und entwickelt allogene Gamma-Delta-T-Zell-Therapien für Autoimmunerkrankungen und Krebs in den Vereinigten Staaten. Der führende Produktkandidat des Unternehmens, Prulacabtagen Leucel (Prula-cel), ist eine allogene Gamma-Delta-T-Zell-Therapie, die einen CAR exprimiert, der auf CD20 abzielt, zur potenziellen Behandlung von Autoimmunerkrankungen. Es entwickelt zudem ADI-212, einen genbearbeiteten und „armorierten" klinischen Kandidaten, der auf das prostataspezifische Membranantigen abzielt. Das Unternehmen wurde 2014 gegründet und hat seinen Sitz in Boston, Massachusetts.
- Employees
- 102
- Headquarters
- Boston, MA
- Address
- 131 Dartmouth Street, 02116 Boston, United States
- Phone
- 650 503 9095
- Website
- adicetbio.com
- IPO Date
- 01/26/2018
- ISIN
- US0070022076
- Stock Split
- 1:16 on 12/30/2025
- Stock Split
- 1:7 on 09/16/2020
Management
| Name | Title | Birth Year |
|---|---|---|
| Chen Schor BA, CPA, M.B.A. | CEO, President & Director | 1972 |
| Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 1981 |
| Lloyd Klickstein M.D., Ph.D. | Interim Chief Medical Officer & Director | 1957 |
| Brian Nicholas Harvey M.B.A. | Chief Financial Officer | 1961 |
| Donald Healey Ph.D. | Chief Technology Officer | 1962 |
| Amy Locke | Chief Human Resource Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/28/2026 Adicet Bio, Inc. (ACET): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 09/08/2026 Adicet Bio, Inc. (ACET): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 09/01/2026 Adicet Bio, Inc. (ACET): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.